Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

693 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients: results of the phase 3, randomized, placebo-controlled PROTOSTAR study.
Prajapati VH, Seyger MMB, Wilsmann-Theis D, Szakos E, Kaszuba A, van Hartingsveldt B, Jett M, Jiang G, Li S, Sinha V, Crauwels H, DeKlotz CMC, Paller AS. Prajapati VH, et al. Among authors: paller as. Br J Dermatol. 2024 Dec 21:ljae502. doi: 10.1093/bjd/ljae502. Online ahead of print. Br J Dermatol. 2024. PMID: 39708367
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registry.
Silverberg JI, Calimlim BM, Grada A, Bunick CG, Gooderham MJ, Shi VY, Obi C, Knapp KD, Munoz B, Crawford JM, Paller AS. Silverberg JI, et al. Among authors: paller as. J Dermatolog Treat. 2024 Dec;35(1):2428729. doi: 10.1080/09546634.2024.2428729. Epub 2024 Dec 11. J Dermatolog Treat. 2024. PMID: 39662888 Free article.
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.
Haft MA, Knapp KD, Claxton A, Munoz B, Crawford JM, Balu S, Kim Y, Schneider S, Eichenfield DZ, Silverberg JI, Eichenfield LF, Bagel J, Rhoads JLW, Paller AS. Haft MA, et al. Among authors: paller as. Curr Med Res Opin. 2024 Dec;40(12):2057-2066. doi: 10.1080/03007995.2024.2427883. Epub 2024 Dec 2. Curr Med Res Opin. 2024. PMID: 39623757
The Role of Amphiphilic Compounds in Nasal Nanoparticles.
Quoc TT, Bíró K, Pető Á, Kósa D, Haimhoffer Á, Lekli I, Pallér Á, Bak I, Gyöngyösi A, Fehér P, Bácskay I, Ujhelyi Z. Quoc TT, et al. Among authors: paller a. AAPS PharmSciTech. 2024 Nov 19;25(8):269. doi: 10.1208/s12249-024-03000-8. AAPS PharmSciTech. 2024. PMID: 39562402
Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years.
Wollenberg A, Ikeda M, Chu CY, Eichenfield LF, Seyger MMB, Prakash A, Angle R, Zhu D, Pontes M, Paller AS. Wollenberg A, et al. Among authors: paller as. J Dermatolog Treat. 2024 Dec;35(1):2411834. doi: 10.1080/09546634.2024.2411834. Epub 2024 Nov 10. J Dermatolog Treat. 2024. PMID: 39522957 Free article. Clinical Trial.
Developing a Core Outcome Set for Netherton Syndrome: An International Multi-Stakeholder e-Delphi Consensus Study.
Nouwen AEM, Ragamin A, Knol MJ, Ott H, Weibel L, Has C, Hovnanian A, Paller AS, Bodemer C, Dalm VASH, Pasmans SGMA, Schappin R; all Netherton Syndrome Core Outcomes Research Evaluation (NSCORE) stakeholders. Nouwen AEM, et al. Among authors: paller as. Dermatology. 2024 Nov 1:1-14. doi: 10.1159/000542215. Online ahead of print. Dermatology. 2024. PMID: 39496226 Free article.
693 results